Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078396 | 0.85 | HDAC4 (0.40) | ALDH1A1CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL6077282 | 0.80 | HDAC4 (0.30) | — | |
| SCHEMBL6077657 | 0.75 | GAA (0.45) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL6077808 | 0.74 | ALDH1A1 (0.36) | ALDH1A1CYP2C9CYP2C19GHSR | |
| SCHEMBL6077929 | 0.73 | LMNA (0.37) | POLBGAA | |
| SCHEMBL6079054 | 0.72 | ALDH1A1 (0.30) | ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6077888 | 0.71 | MMP1 (0.35) | — | |
| SCHEMBL10668988 | 0.70 | HDAC4 (0.54) | ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14952774 | 0.70 | HDAC4 (0.54) | ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6724348 | 0.70 | HDAC4 (0.54) | ALDH1A1CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022317-B2 | Heterocyclic derivatives of 2-oxothiazolidine-4-carboxylic acid, and use as active photoprotective agents | L'OREAL (FR) | 2006-04-04 | — | — | US | claimed |
| US-20050129635-A1 | Novel heterocyclic derivatives of 2-oxothiazolidine-4-carboxylic acid, and use as active photoprotective agents | L'OREAL S.A. (FR) | 2005-06-16 | — | — | US | claimed |
| EP-1471067-A1 | Derivatives of 2-oxothiadiazoline-4-carboxylic acid and its use as active photoprotective agent | L'OREAL (FR) | 2004-10-27 | — | — | EP | claimed |
| US-7022317-B2 | Heterocyclic derivatives of 2-oxothiazolidine-4-carboxylic acid, and use as active photoprotective agents | L'OREAL (FR) | 2006-04-04 | — | — | US | disclosed |
| US-20050129635-A1 | Novel heterocyclic derivatives of 2-oxothiazolidine-4-carboxylic acid, and use as active photoprotective agents | L'OREAL S.A. (FR) | 2005-06-16 | — | — | US | disclosed |
| EP-1471067-A1 | Derivatives of 2-oxothiadiazoline-4-carboxylic acid and its use as active photoprotective agent | L'OREAL (FR) | 2004-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050129635-A1 | Novel heterocyclic derivatives of 2-oxothiazolidine-4-carboxylic acid, and use as active photoprotective agents | CUTA, OGDH, TYR | ALDH1A1 161/4885CYP3A4 443/4885CYP2C9 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.